Clinical study of tazobactam/piperacillin

Abstract

A newly developed, β-lactamase-inhibitor-combined agent for injection, tazobactam/piperacillin, was clinically studied in respiratory tract infections at 1.25-2.5g b. i. d. for 4-21 days.
Excluding the cases of mycoplasmal pneumonia, the clinical efficacy in the sixteen cases was excellent or good in all cases.
No adverse reactions were observed in any patients. Among the lavoratory findings, slightly elevated values of s-GOT and s-GPT were observed in one patient during the administration period.